Identification of a new JNK inhibitor targeting the JNK-JIP interaction site

JNK is a stress-activated protein kinase that modulates pathways implicated in a variety of disease states. JNK-interacting protein-1 (JIP1) is a scaffolding protein that enhances JNK signaling by creating a proximity effect between JNK and upstream kinases. A minimal peptide region derived from JIP1 is able to inhibit JNK activity both in vitro and in cell. We report here a series of small molecules JIP1 mimics that function as substrate competitive inhibitors of JNK. One such compound, BI-78D3, dose-dependently inhibits the phosphorylation of JNK substrates both in vitro and in cell. In animal studies, BI-78D3 not only blocks JNK dependent Con A-induced liver damage but also restores insulin sensitivity in mouse models of type 2 diabetes. Our findings open the way for the development of protein kinase inhibitors targeting substrate specific docking sites, rather than the highly conserved ATP binding sites. In view of its favorable inhibition profile, selectivity, and ability to function in the cellular milieu and in vivo, BI-78D3 represents not only a JNK inhibitor, but also a promising stepping stone toward the development of an innovative class of therapeutics.

[1]  M. Pellecchia,et al.  Development of paramagnetic probes for molecular recognition studies in protein kinases. , 2008, Journal of medicinal chemistry.

[2]  T. Machleidt,et al.  High-throughput cellular assays for regulated posttranslational modifications. , 2008, Analytical biochemistry.

[3]  H. Kaneto,et al.  Oxidative stress and the JNK pathway are involved in the development of type 1 and type 2 diabetes. , 2007, Current molecular medicine.

[4]  M. Czaja,et al.  Tumor Necrosis Factor-induced Toxic Liver Injury Results from JNK2-dependent Activation of Caspase-8 and the Mitochondrial Death Pathway* , 2006, Journal of Biological Chemistry.

[5]  J. Kopeček,et al.  Intracellular targeting of polymer-bound drugs for cancer chemotherapy. , 2005, Advanced drug delivery reviews.

[6]  H. Kaneto,et al.  Possible novel therapy for diabetes with cell-permeable JNK-inhibitory peptide , 2004, Nature Medicine.

[7]  H. Kaneto,et al.  Oxidative stress and the JNK pathway as a potential therapeutic target for diabetes. , 2004, Drug News and Perspectives.

[8]  Sam-Yong Park,et al.  Structural basis for the selective inhibition of JNK1 by the scaffolding protein JIP1 and SP600125 , 2004, The EMBO journal.

[9]  M. Karin,et al.  IKKβ Is Required for Prevention of Apoptosis Mediated by Cell-Bound but Not by Circulating TNFα , 2003 .

[10]  Lee Bardwell,et al.  A Docking Site in MKK4 Mediates High Affinity Binding to JNK MAPKs and Competes with Similar Docking Sites in JNK Substrates* , 2003, Journal of Biological Chemistry.

[11]  Y. Satoh,et al.  JNK: a new therapeutic target for diabetes. , 2003, Current opinion in pharmacology.

[12]  A. Manning,et al.  Targeting JNK for therapeutic benefit: from junk to gold? , 2003, Nature Reviews Drug Discovery.

[13]  M. Karin,et al.  IKKbeta is required for prevention of apoptosis mediated by cell-bound but not by circulating TNFalpha. , 2003, Immunity.

[14]  M. Bogoyevitch,et al.  Identification of the Critical Features of a Small Peptide Inhibitor of JNK Activity* , 2002, The Journal of Biological Chemistry.

[15]  D. Schorderet,et al.  Cell-permeable peptide inhibitors of JNK: novel blockers of beta-cell death. , 2001, Diabetes.

[16]  D. Schorderet,et al.  Cell-Permeable Peptide Inhibitors of JNK: Novel Blockers of β-Cell Death , 2001 .

[17]  Dirk Bohmann,et al.  Diverse functions of JNK signaling and c-Jun in stress response and apoptosis , 1999, Oncogene.

[18]  J. Yasuda,et al.  A mammalian scaffold complex that selectively mediates MAP kinase activation. , 1998, Science.

[19]  Y. Ip,et al.  Signal transduction by the c-Jun N-terminal kinase (JNK)--from inflammation to development. , 1998, Current opinion in cell biology.

[20]  A. Sharrocks,et al.  Differential targeting of MAP kinases to the ETS‐domain transcription factor Elk‐1 , 1998, The EMBO journal.

[21]  M. Karin,et al.  Regulation and function of the JNK subgroup of MAP kinases. , 1997, Biochimica et biophysica acta.

[22]  G. V. Paolini,et al.  Empirical scoring functions: I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes , 1997, J. Comput. Aided Mol. Des..

[23]  M E Greenberg,et al.  A cytoplasmic inhibitor of the JNK signal transduction pathway. , 1997, Science.

[24]  P Willett,et al.  Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.

[25]  Masahiko Hibi,et al.  c-Jun Can Recruit JNK to Phosphorylate Dimerization Partners via Specific Docking Interactions , 1996, Cell.

[26]  R. Davis,et al.  Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways , 1996, Journal of Molecular Medicine.

[27]  H. K. Sluss,et al.  Selective interaction of JNK protein kinase isoforms with transcription factors. , 1996, The EMBO journal.

[28]  C. Miller,et al.  Developmental expression in the mouse nervous system of the p493F12 SAP kinase. , 1996, Brain research. Molecular brain research.

[29]  I. Tsigelny,et al.  JNK2 contains a specificity-determining region responsible for efficient c-Jun binding and phosphorylation. , 1994, Genes & development.

[30]  J Brickmann,et al.  Texture mapping: a new tool for molecular graphics. , 1994, Journal of Molecular Graphics.

[31]  M. Karin,et al.  JNK1: A protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain , 1994, Cell.

[32]  J. Avruch,et al.  pp54 microtubule-associated protein 2 kinase. A novel serine/threonine protein kinase regulated by phosphorylation and stimulated by poly-L-lysine. , 1990, The Journal of biological chemistry.